Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Sepracor-Looks very promising -- Ignore unavailable to you. Want to Upgrade?

To: Iamarangerboy who wrote (10150)	7/18/2007 11:17:58 AM
From: Robohogs	Read Replies (1) \| Respond to of 10280

Data useless as it was holiday week combined with first week of month. Shares looked flattish but my usual sources were not out so I cannot really see them. Of more note: Passed small increase in Xopenex Added rebate for Medicare subscribers Albuterol still heavily favored but may keep 10-30% of that channel. Bill being started for children medicare/medicaid. Some are speculating a rider may be attached re-initiating separate coding for Xopenex. The current one coding move will COST Medicare $200 MM by the way as the average price being used for Xop and albuterol is for all channels and hence will slope down a bit as Xopenex loses share in Medicare channel, but will flatten out as Medicare share flattens at whatever level. Thus, albuterol will be reimbursed so much higher than before, it is a net loss. Jon